McDermott and Bull executive Search
 

Other News

Adagio Medical Reports First Quarter 2025 Results

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the first quarter ended March 31, 2025. Recent Business Highlights: Received Breakthrough Device Designation from the U.S. Food and […]

TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance

Company delivers 42% revenue growth year-over-year and strengthens balance sheet with $22 million gross proceeds from recent private placement Expands commercial footprint, and invests further in new applications for TriNav already in use Updates 2025 guidance to reflect strategic investment in our core liver market and new applications for PEDD […]

Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

PONTE VEDRA, Fla.–(BUSINESS WIRE)–Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced manufacturing and supply chain milestones for its lead drug candidate, tecarfarin, a novel oral vitamin K antagonist (VKA) anticoagulant that is designed to address unmet needs in anticoagulation therapy. “This is […]

Abbott’s Libre® Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes

New data reveal a 78% reduction in cardiovascular disease-related hospitalizations for people living with Type 1 diabetes with prior severe low blood sugar episodes.1 This significant decrease is linked to the use of Libre biowearable technology compared to traditional blood glucose…

Philips Future Health Index 2025: AI poised to transform global healthcare, urging leaders to act now

May 15, 2025AI has the power to cut care delays and manage data overload, but trust gaps among clinicians and patients threaten to slow adoption and impactAmsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has released its 10th annual Future Health Index (FHI) report, highlighting the growing strain on global healthcare systems. The FHI 2025 Report, the largest global survey of its kind analyzing key concerns of healthcare professionals and patients, indicates AI holds promise for transforming care delivery. However, gaps in trust threaten to stall progress at a time when innovation is most needed.“The need to transform healthcare delivery has never been more urgent,” said Carla Goulart Peron, M.D., Chief Medical Officer at Philips. “In more than half of the 16 countries surveyed, patients are waiting nearly two months or more for specialist appointments, with waits in Canada and Spain extending to four months or longer. As healthcare systems face mounting pressures, AI is rapidly emerging as a powerful ally, offering unprecedented opportunities to transform care and overcome today’s toughest challenges.”Long waits, worsening outcomesThe FHI 2025 report reveals 33% of patients have experienced worsening health due to delays in seeing a doctor, and more than 1 in 4 end up in the hospital due to long wait times. “Cardiac patients face especially dangerous delays, with 31% being hospitalized before even seeing a specialist. Without urgent action, a projected shortfall of 11 million health workers by 2030 could leave millions without timely care,” Dr. Peron added.Clinician burnout and data burdens call for digital reliefMore than 75% of healthcare professionals report losing clinical time due to incomplete or inaccessible patient data, with one-third losing over 45 minutes per shift, adding up to 23 full days a year lost by each professional. “These inefficiencies amplify stress on already understaffed teams and contribute to burnout,” said Gretchen Brown, RN, VP and Chief Nursing Information Officer at Stanford Health Care. “Recognizing this, as clinicians, we see AI as a solution and understand that delayed adoption can also carry major risks.”   Of the nearly 2,000 healthcare professionals surveyed, if AI is not implemented:

SeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business Updates

QUELIMMUNE adoption drives four-fold increase in sequential quarter net revenue NEUTRALIZE AKI trial exceeds 50% enrollment, triggers start of Interim AnalysisWebcast Today at 4:30 pm Eastern Time DENVER, May 14, 2025 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU) a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months ended March 31, 2025, and provided business updates on key initiatives. “This is our second full quarter of the QUELIMMUNE launch and we believe our four-fold increase in revenue represents the strong commitment by our customers to improve outcomes in their pediatric patients with Acute Kidney Injury (AKI) with this potential life-saving therapy,” said Eric Schlorff, CEO of SeaStar Medical. “We also continue to attract new customers, including a nationally recognized children’s medical center that just completed Institutional Review Board (IRB) approvals and placed its first order for the QUELIMMUNE therapy.” Mr. Schlorff continued, “Importantly, we are now looking to expand access to our promising technology into the adult AKI market, where this is also a very high unmet need. Our NEUTRALIZE-AKI trial in adult AKI patients is now 50% enrolled and we look forward to completing the trial and potentially filing the Premarket Approval (PMA) application in 2026. Our team is already actively engaging with health care providers in peer-to-peer nephrology venues to provide education and awareness of our Selective Cytopheretic Device (SCD) therapy. Given the same mechanism of action as QUELIMMUNE, albeit a larger device for the adult SCD therapy, we are excited to unveil results from this trial in 2026.” Key Business Highlights in 2025 Since the beginning of 2025, SeaStar Medical’s key business updates include the following: Reported a four-fold increase in QUELIMMUNE net product revenue in the first quarter of 2025 to approximately $293 thousand compared to approximately $68 thousand in the fourth quarter of 2024.Broadened the QUELIMMUNE customer base, securing three new customers in 2025, including a nationally recognized children’s medical center that recently completed IRB approvals and placed an initial order for QUELIMMUNE therapy.Achieved 50% enrollment in the NEUTRALIZE-AKI pivotal trial, triggering the initiation of the prespecified, per protocol Interim Analysis by the trial’s independent Data Safety Monitoring Review Board (DSMB). SeaStar Medical anticipates the DSMB will report its findings to the company in the third quarter of 2025.Awarded two new Breakthrough Device Designations for use of the SCD therapy to treat systemic inflammatory response in 1) adult patients undergoing cardiac surgery and 2) pediatric patients undergoing cardiac surgery towards prevention of post-operative adverse complications and outcomes. This brings SeaStar Medical’s total Breakthrough Device Designations to six therapeutic indications, enabling a potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch.Successfully completed an FDA site inspection of SeaStar Medical’s facility for QUELIMMUNE kitting operations, eliminating its contract manufacturer and enabling internal controls over the entire kitting process.Received from the FDA an Investigational Device Exemption (IDE) for a clinical trial to evaluate the SCD therapy as a bridging strategy to left ventricular assist device (LVAD) implantation in patients with chronic heart failure who have progressed to acute decompensated heart failure. This indication has been granted Breakthrough Device Designation by the FDA.  It represents a market where there is serious unmet need for effective treatments.  Awarded the NKF 2025 Corporate Innovator Award by the National Kidney Foundation for its significant contribution to improving the lives of pediatric patients with AKI based on the approval and introduction of the QUELIMMUNE therapy. Financial Results for the First Quarter 2025 Net revenue for the three months ended March 31, 2025, was approximately $0.3 million, reflecting sales of the QUELIMMUNE pediatric SCD therapy that was approved under a Humanitarian Device Exemption in February 2024 and launched as a commercial product by SeaStar Medical in July 2024. Research and development expenses for the three months ended March 31, 2025, and 2024, were $2.4 million and $1.7 million, respectively. The increase in research and development expenses was primarily driven by an increase in clinical trial costs related to the NEUTRALIZE-AKI pivotal trial, as well as medical affairs and personnel costs, partially offset by a decline in costs for external services. General and administrative expenses for the three months ended March 31, 2025, and 2024, were approximately $1.7 million and $2.3 million, respectively. The decrease in general and administrative expenses was the result of a decline in accounting-related costs, as well as legal-related and consulting expenses, partially offset by an increase in SEC-related expenses. Other expenses (net) decreased approximately $8.8 million for the three months ended March 31, 2025, compared to the three months ended March 31, 2024. The decrease was primarily related to the retirement of outstanding debt obligations and the elimination of convertible notes and related warrants since March 31, 2024. Net loss for the three months ended March 31, 2025, SeaStar Medical was approximately $3.8 million, or $0.44 per share on approximately 8.6 million weighted-average shares outstanding. This compared with a net loss of approximately $12.7 million, or $4.73 per share, on approximately 2.7 million weighted-average shares outstanding for the three months ended March 31, 2024. The Company reported cash, cash equivalents and long-term investments of $5.3 million as of March 31, 2025, compared to $1.8 million as of December 31, 2024. In January 2025 the Company announced an approximately $6.0 million registered direct offering priced at-the-market. SeaStar Medical First Quarter Financial Results Conference Call Date/Time:Wednesday, May 14, 2025, at 4:30 p.m. ET / 2:30 p.m. MT  Webcast:The live webcast and replay can be found here.  Conference ID:2078693  Dial-in numbers:1 (800) 715-9871 within the U.S. 1 (646) 307-1963 from outside the U.S.   A replay of the call will be available after 7:30 pm ET and can be accessed as follows: The webcast replay is available here.The call replay number is 1 (609) 800-9909 and will be available through May 20, 2025. About QUELIMMUNE The QUELIMMUNE™ therapy is being commercialized for children with AKI and sepsis or septic condition weighing 10 kilograms or more who are being treated in the ICU with Renal Replacement Therapy (RRT). The QUELIMMUNE therapy was approved in February 2024 under a Humanitarian Device Exemption application, having met the applicable criteria with clinical results showing safety and probable clinical benefit in a limited population of critically ill children with AKI who have few treatment options. SeaStar Medical commenced its commercial launch of the QUELIMMUNE therapy in July 2025. In January 2025, SeaStar Medical was awarded the 2025 Corporate Innovator Award by the National Kidney Foundation for its significant contribution to improving the lives of pediatric patients with AKI based on the approval and introduction of the QUELIMMUNE therapy. About NEUTRALIZE-AKI Pivotal Trial  The NEUTRALIZE-AKI (NEUTRophil and monocyte deActivation via SeLective Cytopheretic Device – a randomIZEd clinical trial in Acute Kidney Injury) pivotal trial is evaluating the safety and efficacy of the SCD therapy in 200 adults with AKI in the ICU receiving CRRT. The trial’s primary endpoint is a composite of 90-day mortality or dialysis dependency of patients treated with the SCD therapy in addition to CRRT as the standard of care, compared with the control group receiving only CRRT standard of care. Secondary endpoints include mortality at 28 days, ICU-free days in the first 28 days, major adverse kidney events at Day 90 and dialysis dependency at one year. The study will also include subgroup analyses to explore the effectiveness of the SCD therapy in AKI patients with sepsis and acute respiratory distress syndrome.  About Acute Kidney Injury (AKI) and Hyperinflammation  AKI is characterized by a sudden and temporary loss of kidney function and can be caused by a variety of conditions such as sepsis, severe trauma, surgery and COVID-19. AKI can cause destructive hyperinflammation, which is the overproduction or overactivity of inflammatory effector cells and other molecules that can be toxic. Damage resulting from this destructive hyperinflammation in AKI can progress to other organs, such as the heart or liver, and potentially to multi-organ dysfunction or even failure that could result in worse outcomes, including increased risk of death. Even after resolution, these patients may face complications including chronic kidney disease or end-stage renal disease (ESRD) requiring dialysis. Extreme hyperinflammation may also contribute to added healthcare costs, such as prolonged ICU stays and increased reliance on dialysis and mechanical ventilation. About the SeaStar Medical Selective Cytopheretic Device Therapy The Selective Cytopheretic Device (SCD) therapy is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The SCD therapy has broad applications in multiple acute and chronic kidney and cardiovascular diseases, representing nearly a million patients who today have no FDA-approved options for treating their disease. Unlike pathogen removal and other blood-purification tools, the SCD therapy is integrated with an existing continuous renal replacement therapy (CRRT) hemofiltration system to selectively target and transition proinflammatory monocytes to a reparative state and promote activated neutrophils to be less inflammatory. This unique immunomodulation approach may promote long-term organ recovery, eliminate the need for future RRT, including dialysis, and prevent loss of life.   About SeaStar Medical SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. SeaStar’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually. For more information visit www.seastarmedical.com or visit us on LinkedIn or X. Forward-Looking Statements  This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1955. These forward-looking statements include, without limitation, SeaStar Medical’s expectations with respect to anticipated patient enrollment and the expansion of the clinical trial sites; the total addressable market for adult SCD applications; the ability of SeaStar Medical to gain market share and generate sales with respect to the total addressable market for adult SCD applications; the ability of SCD to treat patients with AKI and other diseases; the expected regulatory approval process and timeline for commercialization; and the ability of SeaStar Medical to meet the expected timeline. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to secure additional financing on acceptable terms; (vi) the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations, (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services, (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property, and (ix) other risks and uncertainties indicated from time to time in SeaStar Medical’s Annual Report on Form 10-K, including those under the “Risk Factors” section therein and in SeaStar Medical’s other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.  Contact:  IR@SEASTARMED.COM — Financial Tables to Follow —     SeaStar Medical Holding CorporationCondensed Consolidated Balance Sheets(in thousands, except for share and per-share amounts)     March 31,2025 December 31,2024 (unaudited)  ASSETSCurrent assets   Cash$5,296  $1,819 Accounts receivable, net 110   112 Inventory 44   — Prepaid expenses 1,334   1,835 Total current assets 6,784   3,766 Other assets 813   892 Total assets$7,597  $4,658     LIABILITIES AND STOCKHOLDERS’ EQUITY/(DEFICIT)Current liabilities   Accounts payable$3,397  $3,046 Accrued expenses 3,255   3,188 Notes payable, net of deferred financing costs 363   574 Liability classified warrants 17   33 Total current liabilities 7,032   6,841 Total liabilities 7,032   6,841     Commitments and contingencies (Note 10)           Stockholders’ equity/(deficit)   Preferred stock – $0.0001 par value, 10,000,000 shares authorized at March 31, 2025 and December 31, 2024; no shares issued and outstanding at March 31, 2025 and December 31, 2024 —   — Common stock – $0.0001 par value per share; 450,000,000 and 500,000,000 shares authorized at March 31, 2025 and December 31, 2024, respectively; 9,257,763 and 5,977,246 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively 2   2 Additional paid-in capital 143,899   137,379 Accumulated deficit (143,336)  (139,564)Total stockholders’ equity/(deficit) 565   (2,183)Total liabilities and stockholders’ equity/(deficit)$7,597  $4,658          SeaStar Medical Holding CorporationCondensed Consolidated Statements of Operations(unaudited)(in thousands, except for share and per-share amounts)   Three Months Ended March 31, 2025 2024    Net revenue$293  $— Cost of goods sold —   — Gross profit 293   — Operating expenses   Research and development 2,431   1,697 General and administrative 1,684   2,253 Total operating expenses 4,115   3,950 Loss from operations (3,822)  (3,950)Other income (expense)   Interest expense (11)  (143)Interest income 48   — Change in fair value of convertible notes —   (5,758)Change in fair value of liability classified warrants 16   (2,846)Total other income (expense), net 53   (8,747)Loss before provision for income taxes (3,769)  (12,697)Provision for income taxes 3   — Net loss$(3,772) $(12,697)Net loss per share of common stock, basic and diluted$(0.44) $(4.73)Weighted-average shares outstanding, basic and diluted 8,617,932   2,684,243          SeaStar Medical Holding CorporationCondensed Consolidated Statements of Cash Flows(unaudited)   Three Months Ended March 31, 2025 2024    Cash flows from operating activities   Net loss$(3,772) $(12,697)Adjustments to reconcile net loss to net cash used in operating activities   Amortization of deferred financing costs 11   27 Change in fair value of convertible notes (issued, converted and outstanding) —   5,758 Change in fair value of liability classified warrants (exercised and outstanding) (16)  2,846 Stock-based compensation 167   434 Change in operating assets and liabilities   Accounts receivables, net 2   — Inventory (44)  — Prepaid expenses 501   614 Other assets 79   2 Accounts payable 351   (493)Accrued expenses 67   21 Net cash used in operating activities (2,654)  (3,488)    Cash flows from financing activities   Proceeds from issuance of convertible notes —   979 Proceeds from issuance of shares, net of issuance costs 1,566   4,543 Proceeds from sale of pre-funded warrants 4,785   3,769 Proceeds from exercise of warrants 2   853 Payment of notes payable (222)  (1,813)Net cash provided by financing activities 6,131   8,331 Net increase in cash 3,477   4,843 Cash, beginning of period 1,819   176 Cash, end of period$5,296  $5,019  Supplemental disclosure of cash flow informationThree Months Ended March 31, 2025 2024Cash paid for interest$—  $— Exercise of pre-funded warrants$—  $3,106 Shares issued as payment of convertible notes$—  $9,387 Issuance of convertible note warrants$—  $586 

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

SUNNYVALE, Calif., May 14, 2025 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2025 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management’s formal remarks, there will be a question-and-answer session. Recent Business Highlights CardiAMP® autologous cell therapy in ischemic heart failure of reduced ejection fraction (BCDA-01) On March 30, 2025, two-year results from the double-blind randomized placebo-controlled Phase 3 CardiAMP HF Trial of its CardiAMP autologous minimally invasive cell therapy for the treatment of ischemic heart failure in patients with reduced ejection fraction (HFrEF) were presented as a late-breaking clinical trial at the American College of Cardiology’s Annual Scientific Sessions, demonstrating increased survival, decreased cardiovascular events such as stroke, heart attacks, and hospitalizations and improved quality of life for treated patients at two years. Statistically significant and clinically meaningful improvements were seen in the subset of patients suffering from active heart stress (50% of enrolled patients), as demonstrated by elevated NTproBNP and BNP biomarkers. The Company is on track to share the two-year data with both the FDA and Japan Pharmaceuticals and Medical Devices Agency in the coming weeks and align on pathways to make CardiAMP available for physicians and their patients.The CardiAMP HF II Trial is underway in the United States, with three sites actively enrolling patients. This confirmatory trial focuses on patients with active heart stress with a primary endpoint based on a three-tiered Finkelstein-Schoenfeld hierarchical analysis. The tiers, starting with the most serious events, are (1) all-cause death, including cardiac death equivalents, (2) non-fatal Major Adverse Coronary and Cerebrovascular Events (MACCE), (3) change from baseline in quality of life at a minimum of 12 months and a maximum of 24 months. In the CardiAMP HF Trial, this composite efficacy endpoint was achieved with statistical significance in the subset of patients with elevated NTproBNP that are the focus of the CardiAMP HF II study (p=0.02). CardiAMP autologous cell therapy in chronic myocardial ischemic with refractory angina (BCDA-02) Results from the open-label roll-in cohort of patients having chronic myocardial ischemia with refractory angina to date have shown an average 107 second increase in exercise tolerance and an 82% average reduction in angina episodes at the primary six-month follow-up endpoint compared to before receiving the study treatment. The last roll-in cohort patient has recently reached this six-month primary endpoint, and we intend to prepare the primary results of this cohort for publication and presentation. CardiALLO Cell Therapy in Ischemic Heart Failure (BCDA-03) The low dose cohort of 20 million cells in the phase 1/2 clinical trial was completed in the first quarter 2025 and there have been no treatment-emergent adverse events, arrhythmias, rejection, or allergic responses. The independent Data Safety Monitoring Board recommended that the study proceed as designed in April 2025 based on the 30-day data safety assessment from this cohort. The Company plans to progress the trial to enrollment of 39 participants in the United States and fund development through nondilutive grant applications and partnering. Helix Biotherapeutic Delivery The Company’s Helix transendocardial biotherapeutic delivery system performed well in the recent CardiAMP HF Trial as presented on March 30, with no procedure-related deaths, embolism, or need for surgical cardiac or endovascular repair occurring. This contributes to the growing body of experience using this delivery platform and supports the independent FDA submission for approval that we are currently pursuing. Helix procedures are also now using the advanced Morph DNA bidirectional steerable platform to navigate, and physician feedback has been positive. Intellectual Property The Company’s intellectual property portfolio is robust, with more than 60 patents and patent applications worldwide. In March, the Company announced that the Japan Patent Office granted Japanese Patent No: 7641330 titled “Radial and Transendocardial Delivery Catheter,” with a patent term that will expire on or after September 30, 2034. The patent describes minimally invasive interventional biotherapeutic delivery catheters to deliver biologic therapies to target sites in the heart. This minimally invasive delivery approach enables optimal treatment at the sites where needed, minimizes off-target toxicities, and avoids the need for surgical access to the heart. Two additional patents have also been allowed this year and are expected to issue in the near future. “This has been a great quarter for all of our therapeutic programs in development,” said BioCardia CEO Peter Altman, Ph.D. “Most importantly, the CardiAMP HF Trial has provided significant rigorous evidence supporting both safety and meaningful benefits of CardiAMP cell therapy for heart failure patients who still have elevated biomarkers of heart stress, despite being on maximal guideline directed medical therapy. Our top priorities are the regulatory submissions for the CardiAMP Cell Therapy System clinical consultation with Japan PMDA and for the Helix transendocardial delivery system application for approval in the United States. Both are anticipated this quarter.” First Quarter 2025 Financial Results: Research and development expenses were approximately $1.5 million for the three months ended March 2025 compared to approximately $1.2 million for the three months ended March 2024, primarily due to closeout activities in the CardiAMP HF Trial and the inception of enrollment in the CardiAMP HF II Trial.Selling, general and administrative expenses were approximately $1.2 million for the three months ended March 2025 compared to approximately $1.1 million for the three months ended March 2024.Our net loss was approximately $2.7 million for the three months ended March 2025, compared to approximately $2.3 million for the three months ended March 2024.Net cash used in operations for the three months ended March 2025 was approximately $1.6 million, as compared to approximately $1.5 million for the three months ended March 2024. ANTICIPATED UPCOMING MILESTONES AND EVENTS: BCDA-01: CardiAMP Autologous Cell Therapy for Ischemic Heart Failure CardiAMP HF ManuscriptJapan PMDA Clinical Consultation request / submissionFDA Meeting request / submissionCardiAMP Heart Failure II Trial – additional sites and enrollment BCDA-02: CardiAMP Autologous Cell Therapy in Chronic Myocardial ischemia Completed roll-in cohort data submitted for presentation / publication BCDA-03: CardiALLO Allogeneic Cell Therapy in Inflammatory Ischemic Heart Failure Dose cohort 2 completed enrollment Helix Biotherapeutic Delivery Business FDA approval milestonesPartnering Morph Access Innovations Business Revenues and case reportsIndication specific deals About BioCardia® BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLOTM allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its HelixTM biotherapeutic delivery and Morph® vascular navigation platforms. The CardiAMP Cell Therapy Trial for Heart Failure has been supported financially by the Maryland Stem Cell Research Fund and the Center for Medicare and Medicaid Services. For more information visit: www.BioCardia.com. Forward Looking Statements This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, references to the enrollment in our clinical trials, the availability of data from our clinical trials, filings and communications with the FDA and Japan’s Pharmaceutical and Medical Device Agency, product clearances, the efficacy and safety of our products and therapies, preliminary conclusions about new data, the achievement of any of the anticipated upcoming milestones, our positioning for growth or the market for our products and therapies, the expected benefits of our intellectual property, future prospects, regulatory timelines, and other statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such risks and uncertainties include, among others, the inherent uncertainties associated with developing new products or technologies, regulatory approvals, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue BioCardia’s business and product development plans, the ability to enter into licensing and partnering arrangements and overall market conditions. We may find it difficult to enroll patients in our clinical trials due to many factors, some of which are outside of our control. Slower than targeted enrollment could delay completion of our clinical trials and delay or prevent the development of our therapeutic candidates. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements. We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 26, 2025, under the caption titled “Risk Factors” BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.  BioCardia, Inc.Condensed Consolidated Statements of Operations (Unaudited in thousands, except share and per share amounts)            Three Months endedMarch 31,    2025 2024Revenue:     Collaboration agreement revenue$—$55Costs and expenses:     Research and development 1,530 1,241 Selling, general and administrative 1,196 1,089  Total costs and expenses 2,726 2,330  Operating loss (2,726) (2,275)Other income (expense):      Total other income, net 14 8Net loss$(2,712) $(2,267)       Net loss per share, basic and diluted$(0.59)$(1.35)       Weighted-average shares used in computing   net loss per share, basic and diluted 4,635,764 1,675,539        BioCardia, Inc.     Selected Balance Sheet Data     (amounts in thousands)                   March 31,  December 31,  2025(1)  2024(1)      Assets:     Cash and cash equivalents$949 $2,371Other current assets 224  251Property, plant and equipment and other noncurrent assets 993  1,102Total assets$2,166 $3,724Liabilities and Stockholders’ Equity (Deficit)     Current liabilities$3,234 $2,321Operating lease liability – noncurrent 452  566Total stockholders’ equity (deficit) (1,520)  837Total liabilities and stockholders’ equity (deficit)$2,166 $3,724      (1) March 31, 2025 amounts are unaudited. December 31, 2024 amounts were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission on March 26, 2025.CONTACT: Media Contact:
Miranda Peto, Investor Relations
Email: mpeto@BioCardia.com
Phone: 650-226-0120

Investor Contact:
David McClung, Chief Financial Officer
Email: investors@BioCardia.com
Phone: 650-226-0120

Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones

MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease; Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in Q3 2025 Strong Balance Sheet with $294.4 Million in Cash and Cash Equivalents, Expected to Provide Cash Runway into H2 2027 SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today reported financial results for the first quarter ended March 31, 2025, and reiterated upcoming milestones. “With two clinical programs underway – an important milestone that underscores the strength of our Compass platform and drug development expertise – Maze is entering a new phase of growth,” said Jason Coloma, Ph.D., chief executive officer of Maze. “We’re particularly excited about MZE782, a genetically informed therapy that we believe could be best-in-class for PKU and first-in-class for CKD. We expect to report Phase 1 healthy volunteer data, including biomarker results, later this year to support Phase 2 trials in both indications. In addition, our Phase 2 HORIZON trial of MZE829 continues to actively enroll, on track for a readout in Q1 2026. With a strong balance sheet following our IPO, we’re well-positioned to deliver on our pipeline and mission.” Key Anticipated Milestones MZE829 for APOL1 Kidney Disease (AKD) MZE829 is an oral, small molecule APOL1 inhibitor that Maze is advancing as a potential treatment for patients with AKD, a subset of chronic kidney disease (CKD) estimated to affect over one million people in the United States (U.S.) alone. Maze continues to enroll patients in the Phase 2 HORIZON trial of MZE829. The trial includes a broad population of patients with AKD, including those with diabetes, those with non-diabetic kidney disease, and patients with severe focal segmental glomerulosclerosis (FSGS).Maze expects to announce initial proof-of-concept data from the Phase 2 HORIZON trial in the first quarter of 2026. MZE782 in CKD and Phenylketonuria (PKU) MZE782 is an oral, small molecule targeting the solute transporter, SLC6A19, with potential to be a first-in-class treatment for the approximately five million U.S. patients with CKD who inadequately respond to currently available CKD therapies, as well as potential to be a best-in-class therapy for patients with PKU, an inherited metabolic disorder. MZE782 is currently being evaluated in a Phase 1 clinical trial in healthy volunteers.Maze expects to report initial data, including proof-of-mechanism biomarker results, in the third quarter of 2025.Based on Phase 1 results, Maze plans to initiate two separate Phase 2 clinical trials of MZE782 in CKD and PKU. First Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were $294.4 million as of March 31, 2025, compared to $196.8 million as of December 31, 2024. Maze expects that its current cash and cash equivalents will fund operations into the second half of 2027. Research & Development (R&D) Expenses: R&D expenses were $27.6 million and $21.9 million for the first quarter of 2025 and 2024, respectively. This increase primarily reflects higher clinical trial expenses for MZE829 and MZE782 and personnel-related expenses, including non-cash stock-based compensation expense. General & Administrative (G&A) Expenses: G&A expenses were $7.8 million and $6.1 million for the first quarter of 2025 and 2024, respectively. This increase primarily reflects higher personnel-related expenses, including non-cash stock-based compensation expense, and professional services fees. Net Loss: Net loss was $32.8 million and $32.5 million for the first quarter of 2025 and 2024, respectively. About Maze Therapeutics Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. The company is advancing a pipeline using its Compass platform, which provides insights into the genetic variants in disease and links them with the biological pathways that drive disease in specific patient groups. The company’s pipeline is led by two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for patients. For more information, please visit mazetx.com, or follow us on LinkedIn and X. Forward Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current beliefs and expectations of management. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning the company’s future plans and prospects, any expectations regarding the safety or efficacy of MZE829, MZE782 and other candidates under development, the ability of MZE829 to treat AKD or other indications, the ability of MZE782 to treat CKD, PKU or other indications, the planned timing of the company’s clinical trials, data results and further development of MZE829, MZE782 and other therapeutic candidates, and the sufficiency of the company’s cash and cash equivalents to fund its operating expenses and capital expenditure requirements. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to the company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the company believes the expectations reflected in such forward-looking statements are reasonable, the company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the company’s forward-looking statements due to a variety of factors, including risks and uncertainties related to the company’s ability to advance MZE829, MZE782 and its other therapeutic candidates, obtain regulatory approval of and ultimately commercialize the company’s therapeutic candidates, the timing and results of preclinical studies and clinical trials, the company’s ability to fund development activities and achieve development goals, its ability to protect its intellectual property, general business and economic conditions, and risks related to the impact on its business of macroeconomic conditions, including inflation, volatile interest rates, tariffs, instability in the global banking sector, and public health crises. Further information on potential risk factors that could affect the company’s business and its financial results are detailed under the heading “Risk Factors” included in the documents the company files from time to time with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date of this press release and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. IR/Corporate Contact:Amy Bachrodt, Maze Therapeuticsabachrodt@mazetx.com Media Contact:Dan Budwick, 1ABdan@1abmedia.com   Maze Therapeutics, Inc.Select Condensed Financial Information(in thousands, except share and per share amounts)(unaudited)  Condensed Statements of Operations        Three Months Ended  March 31,  2025  2024 Operating expenses:     Research and development$27,580  $21,877 General and administrative 7,821   6,137 Total operating expenses 35,401   28,014 Loss from operations (35,401)  (28,014)Interest and other income, net 2,615   281 Change in fair value of convertible promissory notes —   (4,761)Net loss$(32,786) $(32,494)Net loss per share, basic and diluted$(1.15) $(13.91)Weighted-average shares of common stock outstanding used to compute net loss per share, basic and diluted 28,628,430   2,336,613            Condensed Balance Sheet Data        March 31,  December 31,  2025  2024 Cash and cash equivalents$294,374  $196,812 Total assets$332,840  $240,542 Total liabilities$40,772  $43,638 Total redeemable convertible preferred stock$—  $508,087 Total stockholders’ equity (deficit)$292,068  $(311,183)